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ABSTRACT
Tissue engineered constructs with autologous adult stem cells capable of selfrepair and growth are highly desired replacements for diseased heart valves. However,
the current approaches have inadequate mechanical properties to withstand in vivo
implantation. Therefore, our group hypothesized that an in vitro environment of
physiological intra-cardiac pressures and flow will stimulate stem cells to differentiate
and remodel valvular scaffold constructs before implantation.
The group developed a pneumatic-driven conditioning system (Aim I) consisting
of a three-chambered heart valve bioreactor, a pressurized compliance tank, a reservoir
tank, one-way valves, pressure-retaining valves, and pressure transducers. The system
can be sterilized using conventional autoclaving and ethylene oxide gas. The most novel
feature is its ability to accommodate all clinically relevant sizes of stented or stentless
biological, mechanical, or tissue engineered substitutes. A tissue derived heart valve
substitute was used to test the bioreactor’s functional capabilities (Aim II) at 60 beats per
minute. The tests resulted in excellent opening and closing of the valve, pulsatile flows
reaching 1400 mL per minute, and aortic pressures reaching 100 mmHg. The bioreactor
then tested tissue engineered heart valves (Aim III) made from decellularized and lightly
cross-linked tissues. Two stentless porcine aortic heart valves were conditioned in the
bioreactor for 21 days. The first was seeded with adipose-derived stem cells (valve 1) and
the second with aortic endothelial cells (valve 2). The third valve was made of valveshaped fibrous sheets encasing a spongy collagen scaffold. It was seeded with human
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bone marrow-derived stem cells (valve 3) and conditioned in the bioreactor for 8 days.
After progressive adaptation, valves were tested at 60 beats per minute and 10 mL per
stroke. Each experiment also included a static control.
The bioreactor created proper closing and opening of the heart valves and allowed
for multiple mounting methods. Results indicated successful cell seeding and attachment
in valves 1, 2, and 3; noticeable intercellular alignment in valves 2 and 3; and stem cell
differentiation in valve 3. Overall, the conditioning system provides a dynamic threedimensional cell culture setting designed to provide optimal physiological conditions for
tissue engineered heart valve development over extended time periods. The group will
continue to develop this approach to study multiple aspects of tissue engineered heart
valve development and heart valve pathology.
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 Cardiac Anatomy & Physiology
The heart has two double-chambered pumps. Figure 1 demonstrates the pressures
and flow through these chambers. The right pump pushes blood through the lungs, where
waste gases are exchanged for nutritional gasses. The left pump propels blood through
the peripheral organs. Each group has two types of chambers. In each case, blood first
enters the superior chamber, the atrium, which helps move blood through an
atrioventricular valve into the ventricle. When these ventricles contract, blood propels
through the pulmonary (right side) or ventricular (left side) valve and through the rest of
the body. Following contraction, the pulmonary and aortic valves close to prevent blood
flow back through the heart (Guyton and Hall, 2006).

Figure 1: Blood flow through the heart. (Darling, ; Guyton and
Hall, 2006)
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This cycle of opening and closing, sudden changes of pressure, and various other
mechanical stresses make heart valves the most mechanically stressed tissues in the body
(Bilodeau and Mantovani, 2006). This is especially true for the aortic valve, where the
pressures are very high compared to the forces on the rest of the valves. These stresses
often cause damage to the valves, in the form of microtears and calcific deposits. Since
the aortic valve is the most stressed, it follows that it is also the most often diseased and
replaced. Therefore, this project has focused on the aortic (Guyton and Hall, 2006).
1.1.1 The Heart as a Pump
The pumping heart is a dynamic feedback system that changes its physical and
chemical outputs according to the body’s needs. However, under average normal resting
conditions, the left heart beats about 70 times per minute (bpm), ejecting 70 mL (stroke
volume) of its left ventricular volume of 120 mL (end-diastolic volume) each beat. This
results in a total of about 4.9 liters of blood flow per minute. The ventricles’ cyclic
contractions create pressures that drive the blood through the circulatory system. When
the left ventricle contracts, the pressure increases to about 120 mmHg. At this point, the
aortic valve snaps shut and blood flows away from the heart along the pressure gradient.
By the time the pressure in the aorta drops to about 80 mmHg, the left ventricle has
begun its contraction to pump another bolus of blood and return the pressure to 120
mmHg. Figure 2 shows the left ventricular volumes and pressures as described above
(Guyton and Hall, 2006).
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Figure 2: The cardiac cycle for the left heart. (Guyton and Hall, 2006)

1.1.2 Aortic Valve Anatomy and Physiology
The physiological composition of a human aortic heart valve is optimized to
withstand high physical stresses and respond to pressure changes during diastolic and
systolic stages of the cardiac cycle. The tricuspid valve is constructed with very strong,
yet very pliable fibrous tissue with three heterogeneous leaflets attached to an annular
ring (Fong, Shin'oka et al., 2006). These leaflets open during systole and press against the
aortic root wall. When they snap close at the start of diastole they meet to create a seal
that can prevent backflow even with the 100 mmHg transvalvular pressure difference.
This cycle maintains efficient unidirectional flow with each heart beat.
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Valve leaflets consist of three layers of tissue that together have the necessary
biomechanical properties to withstand cyclic loading. Table 1 displays each layer’s
composition and function. Figure 3 shows a view of the aortic valve and a cross-sectional
view of a cusp.
Table 1: Composition and function of each valve layer.

Layer

Matrix Composition

Function

Top

Fibrosa

Densely packed circumferencially
aligned collagen; elastin

Maintain durability and stiffness
to withstand 80 mmHg pressure
gradient

Middle

Spongiosa

Loosely arranged collagen;
glycosaminoglycans

Allows shearing between the
ventricularis and the fibrosa
during valve cycle

Bottom

Ventricularis

Densely packed collagen; radially
aligned elastin

Maintains valve resilience, allows
stretch in response to pressure
changes

(Vesely, 2004; Schoen, 2005; Simionescu, 2006)

Figure 3: Aortic valve anatomy. a) aortic valve dissected for viewing (LifeART). b) cross section of a
cusp, showing the three layers present (Vesely, 1998).

4

1.1.3 Aortic Valvular Disease
Aortic valvular heart disease is classified into two main types: 1) stenosis or 2)
regurgitation. There are various causes for each of these problems, but the final outcome
is the same. Patients suffering from valvular heart disease will eventually need a heart
valve replacement (Guyton and Hall, 2006).
In aortic stenosis, the left ventricle fails to empty adequately following
contraction because the aortic valve does not open properly, creating a reduction in the
valvular orifice. In aortic regurgitation, blood flows back into the left ventricle after
contraction because the aortic valve does not close properly (Guyton and Hall, 2006).
Valvular heart disease can be a congenital defect such as improper valve size,
malformed leaflets, or an irregularity in the way the leaflets are attached. It may also be
caused by damage acquired after birth such as calcific deposits, changes in the structure
of the valve, or infections like infective endocarditis and rheumatic fever. Both stenosis
and regurgitation lead to a reduction in the net stroke volume output of the heart, causing
it to work harder to pump the same amount of blood through the body (Clinic).
Eventually, the diseased valve must be replaced.
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1.2 Heart Valve Bioreactors
Bioreactors can be defined “as devices in which biological and/or biochemical
processes develop under closely monitored and tightly controlled environmental and
operating conditions (e.g. pH, temperature, pressure, nutrient supply, and waste removal)”
(Martin, Wendt et al., 2004). Requirements for such bioreactors and examples of previous
aortic valve bioreactors are discussed below.
1.2.1 Bioreactor Requirements
Freed (Freed and Vunjak-Novakovic, 2000) says that a bioreactor must be able to
perform at least one of the following five functions: (1) establish a uniform distribution of
cells on a three-dimensional (3D) scaffold, (2) maintain the desired concentration of
gases and nutrients in the culture medium, (3) provide efficient mass transfer to the
growing tissue, (4) expose developing tissue to physical stimuli, and (5) provide
information regarding the formation process of 3D tissues, which originate from the
isolated cells. This project focused on functions 2, 3, and 4 of Freed’s declared functions.
One of the most important controls of a bioreactor is to supply an adequate
amount of oxygen to a 3D tissue construct. Other biochemical factors, such as carbon
dioxide and wastes also require adequate transport. In conventional cell culture, this is
most often done by creating a large liquid to sterile air interface to facilitate the diffusive
transport of oxygen. In a bioreactor, where the volume of culture medium present is much
larger than in standard cell culture, additional methods must be used. These methods
range from a sterile filter open to the external environment in combination with flow of
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the culture medium (Dumont, Yperman et al., 2002) to coiling gas-permeable tubing
inside a culture medium reservoir (Warnock, Konduri et al., 2005).
Physical stimuli such as tension, compression, shear stresses, pressure,
temperature, and pulsatile flow of culture medium improve the structure and mechanical
properties of engineered tissues (Rabkin and Schoen, 2002; Barron, Lyons et al., 2003).
These mechanical forces have an integral part in regulation of cell phenotype and growth
and the repair or degradation of tissues (Rabkin and Schoen, 2002). Control of transvalvular pressure, pulsatile forces, flow rate, frequency, stroke rate, and stroke volume
are all important design parameters of bioreactor to ensure that the necessary physical
stimuli are integrated into the design (Barron, Lyons et al., 2003).
1.2.2 Current Bioreactors
Current heart valve bioreactors are designed to test a single valve in vitro at
different levels of pulsatile flow under controlled conditions in a standard humidified
incubator at 37°C and 5% CO 2 . Figure 4 shows the common main components of aortic
valve bioreactors, which include a reservoir, mechanical valve, pump, processing
chamber, compliance chamber, resistance, and a filter (Barron, Lyons et al., 2003). This
schematic gives one representative layout of these components, but many bioreactors in
use today have variations on placement, type, and extent of use of these components.
Most bioreactors have control over parameters such as flow, pH, and stroke volume and
can change those parameters as desired to create varying environments for the valves.
One use of the controllable parameters is progressive adaptation, where increasing
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amounts of mechanical stimuli are applied to aid strengthening of the tissue construct and
prevent immediate failure upon implantation.
There are currently numerous individual laboratories across the country using
heart valve bioreactors. Many reviews (Freed and Vunjak-Novakovic, 2000; Rabkin and
Schoen, 2002; Ratcliffe and Niklason, 2002; Barron, Lyons et al., 2003; Martin, Wendt et
al., 2004; Martin and Vermette, 2005; Bilodeau and Mantovani, 2006) contain extensive
comparison and assessment of the variations between them. The bioreactors range in
design, complexity, and function, performing at various levels and accuracy. Valve
mounting methods and modes of assembly vary, often with little options or ability to
accommodate abnormal valve shapes. While many bioreactors are very powerful and can
achieve high pressurization, none have been found to be able to subject valves to the wide
range of synergistic physiological stresses that would be present if the valve were
implanted into the body (Bilodeau and Mantovani, 2006).
Overall, much progress has been made in the area of heart valve bioreactors.
However, there is still room for improvement.
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Figure 4: Schematic diagram of a model pulsatile flow bioreactor. (Barron, Lyons et al., 2003)
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CHAPTER 2: PROJECT APPROACH
2.1 Overview
Existing heart valve replacements provide major improvements in cardiac
function and life expectancy but have significant limitations and require either lifelong
anticoagulation therapy for the mechanical valves or surgical replacement within 15-20
years for tissue derived valves. Thus, tissue engineered constructs with autologous adult
stem cells capable of self-repair and growth are highly desired replacements for diseased
heart valves. In response to the current approaches’ inadequate mechanical properties
upon in vivo implantation, our group hypothesizes that an in vitro environment of
physiological intra-cardiac pressures and flow will stimulate stem cells to differentiate
and remodel valvular scaffold constructs before implantation.
The goal of this master’s project has been to develop, build, and test a pulsatile
bioreactor that will cause a valve to cyclically open and close and will provide the
physiological intra-cardiac pressures and flow to condition tissue engineered heart valves.
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2.2 Specific Aims
This work has three distinct parts: 1) designing and building a heart valve
bioreactor, 2) testing the heart valve bioreactor’s capabilities as a pump, and 3) using the
heart valve bioreactor to test tissue engineered heart valves.
2.2.1 Aim I: Design and Build a Heart Valve Bioreactor
The desired heart valve bioreactor had three fundamental functional requirements:
That 1) the valve open and close cyclically due to a change in trans-valvular pressure, 2)
the pressure be adjustable to simulate intra-cardiac pressures, and 3) the fluid in the
culture system circulate to achieve nutrient and waste transport and create appropriate
sheer stresses on the valve surface. All materials were to be non-toxic and nondegradable. The system was to maintain sterility and visibility of the operation of the
heart valve.
Evaluative design methods provided the basis for the bioreactor’s systematic
design. First, we identified the customers and their wants. Then we identified and
evaluated the competition and developed means to evaluate the customers’ wants. After
setting minimum and optimal values for each desired capability, we identified any
conflicting effects of improving outcomes. After completing the design, the drawings
were drafted, the manufacturing was accomplished, and the system was tested.
2.2.2 Aim II: Test the Heart Valve Bioreactor’s Capabilities as a Pump
The desired environmental conditions of the bioreactor as a pump include 1)
aortic systolic/diastolic pressures reaching at least 120/80 mmHg, 2) flow rates reaching
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5000 mL/min, 3) stroke rate exceeding 60 beats per minute, 4) oxygen and carbon
dioxide levels high enough to support cell and tissue growth, and 5) repeatable conditions.
A bioprosthetic heart valve was used to test the conditioning system under both
light and rigorous conditions. We used flow meters and pressure transducers to evaluate
the bioreactor’s capabilities as a pump in according to the desired conditions.
2.2.3 Aim III: Use the Heart Valve Bioreactor to Test Tissue Engineered
Heart Valves
The desired use of this bioreactor is to create an in vitro environment of
physiological intra-cardiac pressures and flow for the conditioning and testing of tissue
engineered heart valves.
The system’s ability to sustain a freshly collected, living heart valve (valve 1) was
first tested. After that, the bioreactor tested tissue engineered heart valves made from
decellularized and lightly cross-linked tissues. Two stentless porcine aortic heart valves
were tested in the bioreactor for 21 days. The first was seeded with rat adipose-derived
stem cells (valve 2) and the second with porcine aortic endothelial cells (valve 3). The
last valve was made of valve-shaped fibrous sheets encasing a spongy collagen scaffold.
It was seeded with human bone marrow-derived stem cells (valve 4) and conditioned in
the bioreactor for 8 days.
Cellular assays including Live/DEAD, MTS, Diff-Quick, SEM, H&E staining,
and DAPI staining were used to evaluate cell viability and stem cell differentiation.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Bioreactor Design
The bioreactor’s development was approached as a design project. As such,
certain formal methods of design were used to determine the desired qualities of the
system and those qualities’ desired values. The design process closely followed Dym and
Little’s (2004) design book Engineering Design: A Project-Based Introduction. These
methods can also be documented using a quality function development (QFD) chart. The
QFD development process can be found in The Mechanical Design Process by Ullman
(2003). The following subsections detail the use of these design processes.
3.1.1 Customer and Design Goals (Who, What, & Who vs. What)
A fundamental step in any design project is to identify the customers, then move
on to what the customers desire (attributes) from the device. The primary customer for
this project was the principle investigator of the Biocompatibility and Tissue
Regeneration Laboratory (BTRL), Dr. Dan Simionescu. The initial client statement
provided was to “Create a bioreactor to test and condition about 10 replacement heart
valves.”
Expansion of the project revealed additional customers in the form of other lab
members. These included Mary E. “Betsy” Tedder, Ting-Hsien “Tom” Chuang, and Dr.
Agneta Simionescu. Through interviews, a customer questionnaire, and a review of
current devices, a comprehensive design attributes list was compiled and divided into
objectives, functions, and constraints. After pruning and grouping the objectives list, pair-
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wise comparison charts were used to rank the importance of each objective for each user.
These were combined to form a comprehensive ranked objectives list, which helped
develop the objectives tree seen in Figure 5. Using these ranked objectives and a further
understanding of the customers’ desired attributes, an updated client statement was
developed:

“Create a bioreactor to simultaneously test and condition 3-6 replacement
heart valves under physiological mechanical and nutritional conditions.
The vital conditions of the aforementioned environment include cyclic
opening and closing of the valve, aortic systolic/diastolic pressures
reaching at least 120/80 mmHg and oxygen and carbon dioxide levels high
enough to support the growth of the cells and tissues. Flow rates reaching
5000 mL/min and a stroke rate exceeding 60 beats per minute are also
desired. This bioreactor should be consistent in its repeatability of
conditions between cycles and over the life of the bioreactor. All materials
used must be non-toxic and non-degradable. Sterility and visibility of the
operation of the heart valves should be maintained.”

The design was based upon this updated client statement and the previously
mentioned ranking of objectives. Reviewing these items periodically ensured that the
design continued to be what the customers desired.
The design documentation used to identify and develop the customers and
objectives can be found in Appendix A: Design Documentation.
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Figure 5: Objectives tree
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3.1.2 Current Devices’ Capabilities (Now & Now vs. What)
Section 1.2.2 described typical existing heart valve bioreactors. Some of these
bioreactors were extremely similar and some were very different from the desired system.
The desired attributes from all the designs were considered, but only the most closely
related devices were further investigated. Every device was ranked for each of the design
attributes. Those rankings then summarized the most effective means currently
implemented to meet the desired attributes. After this evaluation, it was then possible to
investigate methods of improvement for each design attribute as necessary.
3.1.3 Measurement, Evaluation, and Desired Values (How, How vs. What, &
How Much)
The next step of the design process was to determine how each desired attribute
would be measured (metrics) and the units in which those measurements could be
recorded. Some were fairly obvious, such as desired pressure being measured in mmHg,
while others were less obvious, such as sterilizability being measured in hours taken to
sterilize completely.
After determining the metrics for each attribute, a range of acceptable values was
developed. This range extended from levels at which it was expected that the customer
would be delighted by the outcome to levels at which it was expected that the customer
would be disgusted by the outcome. For example, for maximum attainable flow rate,
disgusted and delighted values of 500 mL/min and 1000 mL/min, respectively were set.
If the final design provided a maximum flow rate less than 500 mL/min, it was expected
that the customers would not be satisfied. However, if the final design provided a
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maximum flow rate of more than 1000 mL/min, it was expected that the customers would
be fully satisfied.
3.1.4 Synergism and Conflictions (How vs. How)
Finally, to give a better understanding of the design, the ways in which improving
one attribute would affect the other attributes was assessed. Some had positive
interactions while others had negative interactions and a balance of improvements had to
be made. More often, improving one attribute had no affect on the performance of other
attributes.
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3.2 Bioreactor Capabilities Testing Using a Bioprosthetic Valve
To demonstrate the achievement of the heart valve bioreactor’s two fundamental
functional requirements, “aortic” pressure, “ventricular” pressure, and fluid flow were
tested. All tests used double-distilled water and a bioprosthetic heart valve (BHV). The
BHV was an expired porcine glutaraldehyde fixed stented aortic valve replacement,
25mm Toronto SPV Valve from St. Jude Medical.
3.2.1 Pressure
The end diastolic- and end systolic- left ventricular and aortic pressure were
determined by obtaining pressure readings from each of the aortic and ventricular
chambers of the bioreactor. Pressure transducers (Cole-Parmer, K-68075-16) were
mounted and a data acquisition system (DAQ) (OMEGA, OMB-DAQ-55) took readings
at 180 Hz. The aortic pressure transducer was approximately 7.5 cm above the valve and
the ventricular pressure transducer was approximately 8.0 cm below the valve. As per
normal settings, the ventilator was set to have an inspiration time of 50%, pause time of
0%, working pressure of 110 cmH 2 O, 60 bpm, and an actual inspiration tidal volume of
138±2mL. The total volume of fluid in the system was estimated to be 1,600 mL. This
fluid was distributed between the bioreactor and two reservoirs: one to be pressurized and
one to serve for gas exchange. The setup of the system can be seen in Figure 6.
Values of pressure were recorded under no pressurization, after an initial
pressurization of the top reservoir using compressed air, and after a second pressurization
of the top reservoir.
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Figure 6: Assembly of bioreactor system for pressure testing.
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3.2.2 Flow
Cyclic flow volume was determined using one flow meter (Cole-Parmer catalog #:
K-32550-07) on each of the two outlet lines from the aortic chamber going to the
reservoir. The top and bottom fluid levels with respect to the bottom of the bioreactor
were 13cm and 9.5cm, respectively. As per normal settings, the ventilator was set to have
an inspiration time of 50%, pause time of 0%, and working pressure of 108 cmH 2 O.
Following one minute of cyclic flow at 60 beats per minute (bpm), the values
were recorded to determine the flow per minute and stroke volumes attainable at these
conditions. The actual inspiration tidal volume was adjusted while keeping all other
variables constant to determine flow capabilities. Each level of actual inspiration tidal
volume was repeated two times (n=2) and the readings averaged.
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3.3 Experimental Methods
The following protocols were used in the experimentation, testing, and analysis of
valves in the bioreactor.
3.3.1 Porcine Aortic Valve Collection and Cleaning
Fresh porcine hearts, with intact ascending aorta, were collected from a local
USDA approved abattoir, Snow Creek Meat Processing, Seneca, SC. The aortic valves
were dissected from the hearts in a section of tissue including the aortic root, aortic valve,
adjacent portion of the mitral valve, and excess muscular tissue on the opposite side as
the mitral valve. Valves were collectively stored in a 500mL bottle of un-buffered, sterile
saline with 2% antibiotics/antimycotics over ice during transportation to the laboratory.
The valves were then cleaned over ice on the lab bench. To clean the valves, the tissue
was trimmed of excess fat, the aortic root was trimmed to a length of about one inch, the
mitral valve was trimmed of excess material, and the muscle was trimmed to a thickness
of less than one mm adjacent to the endocardium.
3.3.2 Tissue Decellularization
To minimize the immune responses, the porcine aortic valves were decellularized
by removing cellular components and Gal-α (1,3) Gal, a porcine specific antigen. This
was performed via steps of hypotonic shock using double distilled water (ddH 2 O),
extraction of cell fragments using 0.05M NaOH then decellularization solution (0.05%
SDS, 0.5% Triton X-100, 0.5% Na-Deoxycholate, and 0.2% EDTA in 10mM TRIS, pH:
7.5), removal of nucleic acids using DNAse/RNAse, and sterilization using 70% EtOH.
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Materials:
• Heart valves
• ddH 2 O
• sterile ddH 2 O
• 70% EtOH
• Sterile 1x PBS
• Sterile suture
• 10mM TRIS (2.42g TRIS in 2L ddH 2 O at pH:7.4-7.5)
• 0.05 M NaOH (2g NaOH in 1L 10mM TRIS)
• Decellularization solution (in 1 Liter 10mM TRIS)
o 0.05% SDS (Sodium Dodecyl Sulfate) (0.5g) – wear a breathing mask
o 0.5% Triton X-100 (5 mL)
o 0.5% Deoxycholic Acid, Sodium Salt (5g) – wear a breathing mask
o 0.2% EDTA (Ethylenediaminetetra-acetic acid) (2g)
• DNAse/RNAse (deoxyribonuclease/ribonuclease) (in 1 Liter PBS)
o 1.015g MgCl 2
o 0.18mg DNAse (360 milliunits/ml)
o 3.7mg RNAse (360 milliunits/ml)
Methods:
1. Rinse valves with ddH 2 O
2. Incubate valves in ddH 2 O overnight at 4°C
3. Incubate valves in 0.05 M NaOH 2 hours at room temperature under agitation
4. Rinse valves w/ddH 2 O (3x)
5. Sterilize valves in 70% EtOH 20 minutes at room temperature under agitation
6. Rinse valves w/ddH 2 O (3x)
7. Incubate in decellularization solution overnight at room temperature under agitation
8. Rinse with ddH 2 O (5-10x)
9. Sterilize valves in 70% EtOH 20 minutes at room temperature under agitation
10. Rinse valves with ddH 2 O (3x)
11. Incubate valves in ddH 2 O 2 hours at room temperature under agitation
12. Incubate in RNAse/DNAse overnight at room temperature under agitation
13. Rinse with ddH 2 O (3x)
14. Suture coronary arteries closed to aid future cell seeding
15. Sterilize valves in 70% EtOH overnight at room temperature under agitation
---- STERILE CONDITIONS: INDIVIDUAL, STERILE, SPECIMEN-CUPS ---16. Rinse with sterile PBS (3x)
17. Incubate valves in sterile ddH 2 O 2 hours at room temperature under agitation
18. Follow with tissue fixation

3.3.3 Tissue Fixation
Heart valve scaffolds were fixed to cross-link the proteins in the valve. They were
treated overnight at room temperature under agitation with 0.075% penta-galloyl glucose
(PGG) in 50mM dibasic sodium phosphate buffer in saline with 20% isopropanol, pH 5.5.
The materials and methods follow.
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Materials (for 500mL):
• Decellularized heart valves
• ddH 2 O
• 70% EtOH
• Sterile 1x PBS
• Saline (3.6g NaCl in 400 mL ddH 2 O)
• 0.075% PGG (Slowly add 400 mL phosphate buffer to 100mL PGG solution and run through 0.22
µM sterile filter system)
o Phosphate Buffer - 50mM Na 2 HPO 4 (2.84g Na 2 HPO 4 in 400 mL saline, pH: 5.5)
o 0.375g PGG dissolved in 100 mL isopropanol
o 0.22 µM sterile filter system
Methods:
1. Rinse with sterile PBS (3x)
2. Incubate valves in sterile 0.075% PGG overnight at room temperature under agitation
1. Rinse with sterile PBS (3x)
2. Sterilize valves in 70% EtOH 20 minutes at room temperature under agitation
3. Rinse with sterile PBS (3x)
4. Follow with cell seeding or store in sterile 0.02% NaN 3

3.3.4 Neutralization and Cellular Seeding
The valve scaffolds were incubated at least 3 hours at room temperature in sterile
Delbecco’s Modified Eagle Medium with 50% fetal bovine serum and 2%
antibiotics/antimicotics to neutralize any phenolic groups from the PGG that may have
been left after fixation. After aspirating the neutralization solution, the valves were stood
upright in individual specimen cups and seeded with the appropriate number of cells in
200 µL of cell culture media for each cusp. Additional cell culture media was placed on
the valves following mounting into the bioreactor.
3.3.5 Live/DEAD® staining
The LIVE/DEAD® Viability/Cytotoxicity Assay Kit (Molecular Probes) is a twocolor fluorescence assay used to stain cells on the surface of the cusps. Intracellular
esterase activity distinguishes live cells via the enzymatic conversion of calcein AM to
calcein, which intensely fluoresces green in live cells. The kit also uses EthD-1, which
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enters cells with damaged membranes and fluoresces upon binding to nucleic acids,
indicating dead cells upon its bright red fluorescence.
The assay was prepared as directed and placed on cusps in a six-well plate. After
the incubation time in the dark, the samples were imaged with the fluorescence
microscope (Invitrogen, 2005).
Materials (for 10mL):
• 1x PBS
• Six-well culture plates
• Live/DEAD® Viability/Cytotoxicity Assay Solution (Molecular Probes) (Vortex the EthD-1 and
PBS, then add calcein and vortex)
o 20 µL EthD-1
o 5 µL 4mM calcein
o 10mL 1x PBS
Methods:
1. Dissect valve leaflet from the valve
2. Rinse leaflet with PBS (1x)
3. Place leaflet in a well of the six-well culture plate
4. Add ~3mL stain to each well
5. Incubate in Live/DEAD® solution 20 minutes at 37°C in the dark
6. Image using FITC and Texas Red filters to examine the cells

3.3.6 MTS
MTS is the common name for the CellTiter 96® AQueous One Solution Cell
Proliferation Assay. It is a colorimetric method used to determine the number of viable
cells present in culture. The reagent combines a tetrazolium compound [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS] and an electron coupling reagent (phenazine ethosulfate; PES) to form a
stable solution. The compound is added to the cells, where it is bioreduced into a colored
formazen product by dehydrogenase enzymes in metabolically active cells. The number
of living cells is directly proportional to the quantity of formazan product as measured by
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the absorbance at 490 nm (Promega, 2007). For this assay, the reagent was added to the
cell culture, incubated for at least one hour, and the absorbance read at 490nm with a 96well plate reader.
3.3.7 Diff-Quick
Diff-Quick staining is a type of Romanowski stain based on a combination of
eosin and methylene blue. It was originally designed to incorporate pink cytoplasmic
staining with blue nuclear staining and fixation as a single step. For this assay, the leaflet
was fixed in the Diff-Quick fixative for 30 seconds, and then rinsed with PBS. Following
fixing, the tissue was stained in Diff-Quick solution II for 10 seconds, rinsed with PBS,
counterstained with Diff-Quick solution I for 10 seconds, rinsed with PBS, and viewed
under the light microscope.
3.3.8 Scanning Electron Microscopy
Scanning electron microscopy was used to image the cusp surface for a threedimensional view of any cells present. After careful dissection from the valves, the cusps
were placed and stored in Karnovsky’s fixative (2.5% glutaraldehyde, 2% formaldehyde
in 0.1 cacodylate, pH=7.4). Following dehydration with ethanol and coating with gold,
the samples were imaged using the Hitachi S4800.
3.3.9 Hematoxylin and Eosin Sections
Hematoxylin & Eosin (H&E) staining is a popular staining method in histology. It
uses the basic dye, hematoxylin, to color basophilic structures, such as those containing
nucleic acids like the cell nucleus, a blue-purple hue. The acidic dye, eosin, colors
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eosinophilic structures, such as cytoplasm and some extracellular matrix products, bright
pink (Ross, Kaye et al., 2003).
Following fixation in 10% formalin, cusps were cut in half, embedded in paraffin
wax, sectioned, and stained according to the following routine H&E staining method.
Orientation of the sections was in the radial direction, crossing (vs. aligning with) the
collagen bundles.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.

Xylene ---------------------- 10 dips
Xylene ----------------------- 5 min
100% EtOH ----------------- 10 dips
100% EtOH ----------------- 1 min
95% EtOH ------------------ 10 dips
95% EtOH ------------------ 1 min
Running Water -------------Till Clear
Distilled Water ------------- 1 min
Hematoxylin --------------- 5 min
Running Water -------------Till Clear
Clarifier ---------------------10-15 dips
Running Water -------------Till Clear
Bluing ----------------------- 1 min
Running Water ------------- 30 sec
95% EtOH ------------------ 10 dips
Eosin ------------------------ 45 sec
95% EtOH ------------------ 10 dips
95% EtOH ------------------ 10 dips
100% EtOH ---------------- 10 dips
100% EtOH ---------------- 10 dips
100% EtOH ---------------- 10 dips
Xylene ---------------------- 10 dips
Xylene ---------------------- 5 min

3.3.10 DAPI Sections
DAPI (4'-6-Diamidino-2-phenylindole) is a florescent stain that will pass through
an intact cell membrane and bind strongly to dsDNA. Thus, it is used extensively in
fluorescence microscopy to stain both live and fixed cells with a corresponding emission
of bright blue fluorescence.(Invitrogen, 2006)
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After performing routine H&E staining, DAPI staining helped validate the
presence of nucleic acids that were difficult to distinguish. Each fixed and paraffinembedded section was brought back to water according to the following steps and stained
directly on the slide.

1.
2.
3.
4.
5.
6.
7.

Xylene ---------------------- 10 dips
Xylene ---------------------- 5 min
100% EtOH ---------------- 10 dips
100% EtOH ---------------- 1 min
95% EtOH ------------------ 10 dips
95% EtOH ------------------ 1 min
Running Water -------------Till Clear
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3.4 Heart Valve Experimentation
The experimental usefulness of the bioreactor was tested using a living valve;
decellularized, fixed, and seeded valves; and a tri-layered valve made from pericardium
and scaffolding. In all, fifteen experiments were performed. These consisted of the
following four types; one set of results will be shown for each type.
3.4.1 Valve 1: Living Valve – 7 Days
Valve preparation
Valves were collected from Snow Creek Meat Processing, Seneca, SC and
cleaned as described in section 3.3.1. Modifications to the above protocol consist of
cleaning the valves in the sterile hood instead of on the lab bench.
Bioreactor conditions
Following cleaning, the living valve was mounted in the bioreactor in DMEM
with 10% fetal bovine serum and 1% antibiotics/antimycotics. That valve was then tested
at 60 bpm and 60 mL of air per stroke for seven days inside the incubator at 37°C and 5%
CO 2 . A static control valve was kept in a specimen cup in the incubator, next to the
bioreactor.
Analysis
After dissection, the cusps of the valves were cut away from the valve wall and
the MTS, Live/DEAD and Diff-Quick assays were performed as listed in Table 2.
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Table 2: Experimental conditions & assays for living valve experiment (3.4.1).

Valve 1

1-150-Living
1-150-Static

Cusp

Valve 2

ID

Number
of Days

1a
1b
2a
2b
3a
3b
1a
1b
2a
2b
3a
3b

Conditioning specifications
beats
stroke
%
per
volume °C CO
minute
(mL)
2

7

60

15

37

5

7

0

0

37

5

Assay Performed
Live/Dead
DiffQuick
Live/Dead
MTS
Live/Dead
MTS
Live/Dead
DiffQuick
Live/Dead
MTS
Live/Dead
MTS

3.4.2 Valve 2: Endothelial Cell Seeded Valve – 21 Days
Valve preparation
Eight valves were collected from Snow Creek Meat Processing, Seneca, SC and
cleaned as described in section 3.3.1. Following decellularization (3.3.2 – Modifications
include step 2: Incubate valves in ddH 2 O overnight at room temperature under agitation)
and tissue cross-linking (3.3.3), the valves were stored in 0.02% NaN 3 . Four valves (see
Table 3) were used for this experiment as selected by visual opening and closing between
step 14 and 15 in section 3.3.2: Tissue Decellularization. These valves included a time
zero day, non cell-seeded valve (T0DC), a time zero day, cell-seeded valve (T0C), a time
21 day static control (T21S), and a time 21 day dynamic test valve (T21D).
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Cellular specifications
After seven days of storage, the four selected valves were rinsed and stored in
sterile saline for two days at 4°C to remove any residual NaN 3 . This was followed with
neutralization and cell seeding (3.3.4). 1E5 porcine aortic endothelial cells at passage 6
were

seeded

per

cusp.

MCDB

with

10%

fetal

bovine

serum

and

2%

antibiotics/antimycotics without cells was used as a control for valve T0DC.
Bioreactor conditions
The test valve was mounted in the bioreactor and progressive adaptation over the
course of 20 hours was used to bring the pumping conditions to 60 bpm and 10mL per
stroke. DMEM with 10% fetal bovine serum and 2% antibiotics/antimycotics was used
and changed every seven days for all samples. Of note is that after the first seven days,
the culture media in the bioreactor began to appear cloudy. The cell culture media in the
system was changed as soon as possible after noticing this. Cloudiness did not return for
the remainder of the experiment. Static controls as listed in Table 3 were placed in
specimen cups in the incubator next to the bioreactor at 37°C and 5% CO 2 .
Analysis
After one night in the incubator and dissection of cusps from the valve wall, the
cusps of valves T0C and T0DC were analyzed according to the assays listed in Table 3.
After 21 days, the cusps of valves T21D and T21S were analyzed according to the assays
listed in Table 3.
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Table 3: Experimental conditions & assays for endothelial cell experiment (3.4.2).

2-083-T0C
2-083-T0DC
2-083-T21D
2-083-T21S

Valve 4

Valve 3

Valve 2

Valve 1

ID

Conditioning specifications
Number
stroke
Cusp Cells
of Days beats per volume °C %
minute
CO 2
(mL)
1a
1E5
1b
2a
over1E5
0
0
37 5
night
2b
3a
1E5
3b
1a
0
1b
2a
over0
0
0
37 5
night
2b
3a
0
3b
1a
1E5
1b
2a
1E5
21
60
10
37 5
2b
3a
1E5
3b
1a
1E5
1b
2a
1E5
21
0
0
37 5
2b
3a
1E5
3b
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Assay Performed

SEM
DNA (not performed)
Protein (not performed)
Live/Dead H&E DAPI
SEM
DNA (not performed)
Protein (not performed)
Live/Dead H&E DAPI
SEM
DNA (not performed)
Protein (not performed)
Live/Dead H&E DAPI
SEM
DNA (not performed)
Protein (not performed)
Live/Dead H&E DAPI

3.4.3 Valve 3: Adipose-derived Stem Cell Seeded Valve – 21 Days
This experiment was performed in collaboration with Dr. Aggie Simionescu and
Christopher Albers.
Valve preparation
Valves were collected from Snow Creek Meat Processing, Seneca, SC and
cleaned as described in section 3.3.1. Decellularization (3.3.2) and tissue cross-linking
(3.3.3) followed. Conditions for the two valves used for this experiment can be seen in
Table 4.
Cellular specifications
After neutralization the valves were seeded (3.3.4) with rat adipose derived stem
cells. 5E4 cells/cm2 were seeded in each cusp.
Bioreactor conditions
The test valve was mounted in the bioreactor in DMEM with 10% fetal bovine
serum and 1% antibiotics/antimycotics and progressive adaptation was used to bring the
pumping conditions to 60 bpm and 10mL per stroke. A static control was placed in a
specimen cup in the incubator next to the bioreactor at 37°C and 5% CO 2 . Media was
changed every seven days for all samples.
Analysis
After 21 days and dissection of cusps from valve walls, the cusps of valves T21D
and T21S were analyzed according to the assays listed in Table 4.
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Table 4: Experimental conditions & assays for stem cell experiment (3.4.3).

Valve 1

2-118-T721D
2-118-T21S

Cusp

Valve 2

ID

Number
of Days

1a
1b
2a
2b
3a
3b
1a
1b
2a
2b
3a
3b

Conditioning specifications
beats
stroke
%
per
volume °C CO
minute
(mL)
2

7

60

10

37

5

7

0

0

37

5

Assay Performed
Live/DEAD
H&E
DAPI
Live/DEAD
H&E
DAPI
Live/DEAD
H&E
DAPI
Live/DEAD
H&E
DAPI
Live/DEAD
H&E
DAPI
Live/DEAD
H&E
DAPI

3.4.4 Valve 4: Tri-layered Tissue Engineered Heart Valve – 8 Days
This experiment was performed in collaboration with Dr. Dan Simionescu and
Mary E. “Betsy” Tedder.
Valve preparation
Porcine pericardium and porcine pulmonary artery from 2+ year pigs were
received from Animal Technologies, Inc., Tyler, Tx, and cleaned of all tissue and
extraneous fat/loose connective tissue over wet ice. Following decellularization (3.3.2),
the tissue was subjected to elastase treatment (10 u/mL). Figure 8 shows the process of
forming the valve from these scaffolds. To form the tri-layered valves, silicon molds and
counter molds were made from aortic valves. Those counter molds were then used to
shape the collagen pericardium scaffolding into aortic roots and leaflets. After crosslinking (3.3.3) of the new valve, the original leaflets of the valves were removed and the
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scaffolds were then sutured to the original aortic root from where it was created, forming
the ventricularis and fibrosa layers of an aortic tricuspid valve.
Cellular specifications
Following a rinsing, the valve and external pulmonary scaffold were neutralized
(3.3.4) and each pulmonary artery scaffold was seeded with 5E4 human bone marrowderived stem cells. Figure 7 shows the pulmonary scaffold after insertion between the two
layers of pericardium scaffolding, which were later glued together to form the pocket.
After one night in the bioreactor, a leaflet that was impeding the opening and closing of
the other two was dissected and its spongiosa layer was placed in a six-well plate as a
static control.
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Figure 7: Cross sectional view of
the tri-layered leaflet.
(Courtesy of Dr. Dan Simionescu)

Figure 8: Formation of the tissue engineered heart valve. (a-d) silicon molds and counter-molds
made from aortic valves. (e-i) layered collagen scaffolds shaped as aortic roots. (j) Aortic root
constructs were cut open to show internal structures. Final construct was prepared by gluing layers at
the cusp levels (k), welding free edges (m) and suturing above the sinuses (n). Gluing and welding
were done here only for demo purposes (see next steps). The construct was then sutured to the
original aortic root (from which the silicon mold was created) maintaining the proper orientation (o);
cell-seeded spongiosa was then placed between the two fibrous layers (p), the cusp edges sealed with
glue (q) and the aortic root closed and rinsed for implantation into the heart valve bioreactor (r).
(Data and photos courtesy of Dr. Dan Simionescu and Mary E. “Betsy” Tedder)
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Bioreactor conditions
The valve was mounted into the bioreactor in DMEM with 10% fetal bovine
serum and 1% antibiotics/antimycotics and progressive adaptation over a time period of
three days was used to bring the pumping conditions to 60 bpm, 33% inspiration time,
and approximately 18 mL per stroke. Media in the bioreactor was not changed, but media
in the static control was changed every three days. The static control was placed in the
incubator next to the bioreactor at 37°C and 5% CO 2 .
Analysis
After a test period of eight days, the spongiosa layers of the valves were analyzed
according to the assays listed in Table 5.

TEHV

1

TEHV

2

TEHV

Valve
Cusp
Section

Table 5: Experimental conditions & assays for tri-layered tissue engineered heart valve
(3.4.4).

3

a
b
c
a
b
c
a
b
c

Number
of Days

Conditioning specifications
beats
stroke
%
per
volume °C CO
minute
(mL)
2

8

60

18

37

5

8

60

18

37

5

8

0

0

37

5
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Assay Performed
Live/Dead
DAPI
DAPI + Vimentin
Live/Dead
DAPI
DAPI + Vimentin
Live/Dead
DAPI
DAPI + Vimentin

CHAPTER 4: RESULTS
4.1 Bioreactor Design
A pneumatic-driven conditioning system (Figure 9), was developed that consists
of a three-chambered heart valve bioreactor (1), a webcam for viewing (2), a pressurized
compliance tank (3), a reservoir tank (4), one-way valves (5), pressure-retaining valves
(6), pressure transducers (not shown), an air filter for gas exchange (7), and a pump
(Siemens 900E) to power the cyclic fluid flow (8). The acrylic bioreactor can be
sterilized using conventional methods and accommodates all clinically relevant sizes of
stented or stentless biological, mechanical or tissue engineered substitutes. Other features
of the bioreactor include an unobstructed observation area for the camera, a modular
design allowing easy replacement of cell culture media, and multiple ports for media
sampling.

Figure 9: Culture system schematic
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The developed bioreactor seen in Figure 10 is composed of three transparent
compartments. Made of acrylic plastic, it is 6 inches in diameter, approximately 8.5
inches tall, and completely transparent. The three parts of the bioreactor are held together
by stainless steel screws.
The air chamber (A) is connected to the external pump and is the only chamber
not filled with culture medium. It is separated from the pumping chamber (B) by clear
silicone rubber. Through the power of the external air pump, this membrane bulges into
the pumping chamber and pushes the residing media through the heart valve (C) into the
aortic chamber (D). Once completed, the pump releases pressure in the air chamber,
allowing the membrane to fall down and draw culture medium in through the one way
valves from the reservoir tank to fill the pumping chamber in preparation for the next
cycle. Figure 11 demonstrates this pumping action.
During the pumping phase, the curvature of the pumping chamber and angle of
media inlets ensures consistent distribution of culture medium throughout the chamber.
Once through the valve, the medium enters the aortic chamber then flows into the
compliance chamber. The clear, flat top of the aortic chamber facilitates the viewing of
the functioning of the heart valve. Both the aortic and pumping chambers have multiple
ports for easy access of pressure transducers, media in/outlets, or other probes.
The special removable valve holder in the design is able to adapt to valves of all
sizes and types. The holder is mounted to the inferior side of the aortic chamber with
stainless steel screws. With the addition of a sealing cover, the aortic chamber has the
additional benefit of creating a sterile chamber that can be used to transport the valve.
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Figure 10: Picture and computer aided drafting representation of assembled bioreactor.

Figure 11: Cross-sectional view of the bioreactor demonstrating the pumping actions.
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4.2 Bioreactor Capabilities Testing Using a Bioprosthetic Heart
Valve
The desired environmental conditions of the bioreactor as a pump included 1)
aortic systolic/diastolic pressures reaching at least 120/80 mmHg, 2) flow rates reaching
5000 mL/min, 3) stroke rate exceeding 60 beats per minute, 4) oxygen and carbon
dioxide levels appropriate to support the growth of the cells and tissues, and 5)
repeatability of these conditions.
Testing the conditioning system design revealed that most of these conditions
were met. Sections 4.2.1 and 4.2.2 show results related to the desired pressures and flows,
respectively.
4.2.1 Pressure
Section 3.2.1 describes the setup for pressurizing the system. Under these
conditions, values of pressure were recorded under no pressurization, after an initial
pressurization of the top reservoir using compressed air, after a second pressurization of
the top reservoir, and after all pressure was released from the system in both the aortic
chamber and ventricular chamber of the bioreactor. Figure 12 illustrates pressures
experienced in this experiment. Figure 13 details the non-pressurized section and Figure
14 shows the sustained pressurized section. Figure 12 and Figure 13 reveal the effects of
taking readings through the DAQ at 180 Hz. Only three data points were plotted per
second, creating a “low resolution” pressure profile.
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Figure 12: Chamber pressures. a) no added pressure b) initial pressurization c) additional pressurization
d) release of all pressure
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Figure 13: Chamber pressures without external application of pressure
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Figure 14: Chamber pressures with external application of pressure
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4.2.2 Flow
As section 3.2.2 described, fluid flow through the system was measured at
increasing, incremental values. Table 6 shows the resulting stroke volumes at 60 bpm for
as the value of inspiration tidal volume of air (mL) set for the ventilator is increased. As a
result, the total volume of fluid flow per minute ranges from 284 mL/min to 1336
mL/min. Of note is that for inspiration tidal volume air settings of 7.5 and 10 mL, the
BHV was only slightly opening. Figure 15 shows a graphical representation of the same
data, that can be used to find the ventilator settings necessary to achieve a desired stroke
rate. Figure 16 shows the same for the total fluid flow per minute.
Table 6: Stroke volumes at 60
beats per minute
Inspiration Tidal
Stroke
Volume Air (mL) Volume (mL)
7.5*
10*
20
50
80
100
130

4.7
6.2
8.6
14.3
17.5
18.7
22.3
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Air to Fluid Stroke Volume

Fluid Stroke Volume (mL)

25.0
130, 22.3

20.0
100, 18.7
80, 17.5
15.0
50, 14.3
10.0
20, 8.6
10, 6.2
7.5, 4.7

5.0
0.0
0

20

40

60
80
Air Stroke Volume (mL)

100

120

140

Figure 15: Stroke volume for multiple settings of the ventilator. Use this graph to determine how to
set the the air stroke volume on the ventilator for a desired fluid stroke volume through the valve.
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Figure 16: Total fluid flow through the valve per minute.
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4.3 Heart Valve Experimentation
Fifteen experiments tested four types of valves. The first was a living valve that
was mounted within hours of harvesting. The second and third valves were decellularized,
fixed, and seeded with either porcine aortic endothelial cells or rat adipose-derived stem
cells, respectively. The fourth valve was made of decellularized, fixed, valve-shaped
fibrous sheets encasing a spongy collagen scaffold seeded with human bone marrowderived stem cells. Figure 17 shows macroscopic images of these valves with a summary
of the experimental conditions for each. The bioreactor successfully maintained an
environment conducive to cell survival and differentiation. It provided the desired factors
for the desired amount of time. Figure 17 shows an overview of each valve and detailed
results for each valve type are below.
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4.3.1 Valve 1: Living Valve – 7 Days
Visual analysis of the Diff-Quick staining revealed that the cells were less dense
in the dynamic cusp than in the static cusp. Live/DEAD imaging revealed similar
numbers of live cells between the two groups. However, a slightly higher number of dead
cells were present in the dynamic cusp than in the static cusp. Figure 18 shows
representative images of the Diff-Quick and Live/DEAD assays.
Table 7 shows the MTS assay supporting these findings in both the static and
dynamic cusps. The increase in the cell solution’s optical density (OD) after the
incubation period in both the static and dynamic cusps signified the presence of living,
metabolically active cells, but corresponding to the visual analysis of the Live/DEAD and
Diff-Quick assays, the OD of the dynamic cusps was 15% lower than that of the static
cusps.
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Figure 18: Results of the living valve experiment, 7 days.
Diff-Quick, nucleus = blue, cytoplasm = red/pink; Live/DEAD, live = green, dead = red.
Table 7: Optical density of culture solution via MTS assay.
Optical Density Wet Weight
Mean OD
Cusp 1 Cusp 2 Cusp 1 Cusp 2 per mg Wet
T7-Static
2.88
2.13 71.04 50.27
0.0414
T7-Dynamic 1.50
1.44 40.58 42.19
0.0355

48

Standard OD per Avg Cusp
Deviation Weight = 50mg
0.00122
2.07
0.00190
1.77

4.3.2 Valve 2: Endothelial Cell Seeded Valve – 21 Days
Figure 20 and Figure 22 provide results from this experiment at time = 0 days.
Figure 21 and Figure 23 reveal the results at time = 21 days. Histological sections show
successful initial decellularization in all samples. Cells were successfully seeded and cells
remained present on all appropriate groups for the entire experiment. While some cellular
alignment is in all groups, there is notably more in the valve under dynamic conditions
than in any other valve. SEM imaging revealed that most cells were located near the base
of the cusp rather than near the free edge of the cusp. SEM imaging identified significant
morphological, alignment, density, and locational differences.
Inspecting the solution of Live/DEAD stain used for the time = 21 days revealed
many cells present in that solution after transferring the cusp. Figure 19 shows this
solution and the cells that detached during manipulative handling.

Figure 19: Live/DEAD staining solution.
Live/DEAD, live = green, dead = red.
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Figure 20: Results of the endothelial cell experiment, 0 days.
Live/DEAD, live = green, dead = red.; DAPI, nucleus = blue.
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B
(DAPI staining & photos courtesy of Mary E. ”Betsy” Tedder)
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Figure 21: Results of the endothelial cell experiment, 21 days.
Live/DEAD, live = green, dead = red.; DAPI, nucleus = blue.
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B
(DAPI staining & photos courtesy of Mary E. ”Betsy” Tedder)
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Figure 22: SEM images from the endothelial cell experiment, 0 days, no cells, static.
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Figure 23: SEM images from the endothelial cell experiment, 0 days, cells, static.
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Figure 24: SEM images from the endothelial cell experiment, 0 days, cells, static.
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Figure 25: SEM images from the endothelial cell experiment, 21 days, cells, static.
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Figure 26: SEM images from the endothelial cell experiment, 21 days, cells, static.
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Figure 27: SEM images from the endothelial cell experiment, 21 days, cells, dynamic.
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Figure 28: SEM images from the endothelial cell experiment, 21 days, cells, dynamic.
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4.3.3 Valve 3: Adipose-derived Stem Cell Seeded Valve – 21 Days
Figure 29 reveals histological sections show successful decellularization of the
cusps in this experiment. The yellow arrows notes the presence of seeded cells at time =
21 days. DAPI imaging confirmed the presence of cells at time = 21 days in the H&E
sections.

Figure 29: Results of the adipose-derived stem cell experiment, 21 days.
Live/DEAD, live = green; DAPI, nucleus = blue.
For ease of viewing, digitally altered images of DAPI staining can be found in Appendix B
Live/DEAD staining & photos courtesy of Dr. Aggie Simionescu and Christopher Albers)
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4.3.4 Valve 4: Tri-layered Tissue Engineered Heart Valve – 8 Days
Figure 31 shows that human bone marrow-derived cells survived on the spongiosa
layer of the tissue engineered heart valve in static and dynamic conditions for eight days.
Cells in the dynamic conditions of the bioreactor were more elongated and stained more
heavily for vimentin than those under static conditions. For comparison, Figure 30
includes images of porcine valvular interstitial cells stained for vimentin (red) and
smooth muscle cell actin (red).

Figure 30: Actin vs. vimentin in valvular insterstitial
cells for comparison.
actin = red, nucleus = blue, vimentin = red.
(Staining & photos courtesy of Dr. Dan Simionescu and
Mary E. “Betsy” Tedder)
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Figure 31: Results of the tissue engineered heart valve experiment, 8 days.
Live/DEAD, live = green; DAPI, nucleus = blue; Vimentin, nucleus = blue, vimentin = red.
(Staining & photos courtesy of Dr. Dan Simionescu and Mary E. “Betsy” Tedder)
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CHAPTER 5: ANALYSIS AND DISCUSSION
5.1 Bioreactor Design
The final product demonstrates that the objectives and wants of the customer were
routinely reviewed during the design process to ensure that they were followed. The
valve successfully opened and closed in every experiment, the system enabled pressures
to be easily altered, and flow was adequate to ensure proper nutrient and waste transport.
Throughout the project, the bioreactor was consistent, reproducible, non-toxic, and
maintained the visibility of the heart valve using a webcam, which broadcasted the
playback on the internet.
Unlike other heart valve bioreactors in the literature, the Clemson heart valve
bioreactor is able to test all clinically relevant sizes of stented or stentless biological,
mechanical, or tissue engineered valve substitutes. It’s variable mounting method can
adjust for variant thicknesses of the base, rigidities of the aortic root, and even amounts
of material that would normally be used for mounting. Throughout the fifteen pilot tests,
each variance in valves was seen and mounted at least once.
The greatest weakness of the Clemson bioreactor its ability to maintain a sterile
environment. The large number of pieces, time it takes to assemble, and frequent media
changes all contribute to the risk of contamination. Eventually, as we learned how to
properly handle, assemble, and change media in the bioreactor, sterility problems
occurred less often. We considere this hindrance solved, as the last set of experiments
performed had no contamination present.
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5.2 Bioreactor Capabilities Testing Using a Bioprosthetic Heart
Valve
The final design of the bioreactor system is able to achieve the desired
environmental conditions, but it does not reach all the goals given in the revised client
statement for it’s qualities as a pump. It supplied the physiological conditions of cyclic
opening and closing, nutrient content, and stroke rate. However, the bioreactor system
was unable to achieve a flow rate of up to 5000 mL/min or pressures reaching 120/80
mmHg. The flow rate and pressures it reached were approximately 1350 mL/min and
100/70 mmHg, respectively. These values are not quite physiological, but they are
comparable to those of many other bioreactor designs. By using an alternative pumping
mechanism, modifications could be made to increase these values.
Flow rate and pressure do not yet meet physiological levels, but at the current
stage of tissue engineering, this is not an issue. Current tissue engineered heart valves
must go through steps of progressive adaptation, with flow and pressure beginning at
values much lower than those that the Clemson bioreactor can reach. As the technology
improves and valves get closer to implantation, we will need to be able to reach the
higher values to represent physiological conditions, but for now the current maximum
values are more than adequate to for the initial stages of tissue engineered heart valve
development.
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5.3 Heart Valve Experimentation
The four valve experiments shown of the fifteen performed were a wide
demonstration of the bioreactor’s capabilities, from keeping living tissue alive, to the
differentiation of stem cells. These tests adequately show the functionality of the
designed heart valve bioreactor.
Many of the cells on the living valve were still viable after one week under static
conditions and in the bioreactor. Extended experiments will help determine the different
effects of static and dynamic culture on cell viability, but these results are useful to show
that the bioreactor is capable of supporting cellular life in large quantities of culture
media with the closest air-media interface occurring more than 20 cm away.
The endothelial cell seeded valve experiment was successful in many
ways. Histological sections of the non-seeded valve demonstrated efficacy of the
decellularization method. Endothelial cells initially attached to the valve surfaces and
remained for 21 days under both static and dynamic conditions, but the differences
between the cells subjected to those conditions are great. Though we were unable to
quantify cell proliferation, we saw more cells present and alive in the dynamic conditions
than in the static conditions after 21 days.
Live/DEAD imaging of the dynamic cusp surfaces showed cellular alignment
around certain structures believed to be the large collagen bundles present in the cusp’s
circumferential direction. Scanning electron microscopy (SEM) confirmed and
strengthened this finding, revealing some alignment on the static cusp, but notably greater
alignment on the dynamic cusp. Also of note is that on the dynamic valve, the cells on
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“top” of the collagen bundles were lined up in the circumferencial direction of the bundle
while the cells on the base or in the “valleys” of the bundles were often lined up in the
longitudinal direction of the bundles.
Perhaps the most apparent difference between the cells on the static valve with the
cells on the dynamic valve was the morphology. SEM was crucial in these findings. Cells
under static conditions for 21 days were often flattened and fairly dendritic. Cells under
dynamic conditions for 21 days were either flattened or more rounded, but did not exhibit
dendritic structures to the same extent as the cells under static conditions.
After analyzing the solution of Live/DEAD stain for the 21-day valves we found
that many cells were lost during the transfer of the cusp from the staining solution to the
imaging well. This suggests a greater number of cells present on the cusps than the
Live/DEAD images present. It also suggests that seeded cusps are sensitive to handling
and future experiments should use a “no-touch” technique for all tissue handling to
prevent sloughing off of any cells.
The adipose-derived stem cell seeded valve showed that stem cells would
remain on the cusp scaffolds for three weeks. DAPI confirmed the presence of these
seeded cells on the static and dynamic valve.
Human bone marrow-derived stem cells expressed signs of differentiation after
just 8 days in the bioreactor that were not present to the same extent in the static control.
The cells’ expression of vimentin demonstrates that the stem cells had differentiated into
a fibroblast-like phenotype. Vimentin is also one of the markers used to identify valvular
interstitial cells, which resemble both smooth muscle cells and fibroblasts. This implies
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that the bioreactor is aiding the differentiation of these cells into cells that resemble
valvular interstitial cells.
Overall, results indicated successful cell seeding and attachment in all appropriate
valves, noticeable intercellular alignment in the seeded valves, and stem cell
differentiation in the human bone marrow-derived stem cell seeded valve. The
conditioning system provides a dynamic, three-dimensional cell culture setting to provide
optimal physiological conditions for tissue engineered heart valve development over
extended periods. This approach will be further developed to study multiple aspects of
tissue engineered heart valve development and heart valve pathology.
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CHAPTER 6: CONCLUSIONS
1) The bioreactor is adaptable for any clinically relevant valve and caused all types of
heart valves to cyclically open and close.
2) Flow, pressure, and stroke rate can be controlled and reproduced in the bioreactor.
Though they do not reach physiological levels, conditions of flow and pressure
achieved are adequate for conditioning tissue engineered heart valves.
3) The treated surface of the decellularized, fixed, and neutralized valves was
compatible with porcine aortic endothelial cells, rat adipose-derived stem cells, and
human bone marrow-derived stem cells.
4) Cell viability can be maintained in the bioreactor for at least three weeks, as
demsonstrated with four cell types, including native cells.
5) The bioreactor creates adequate force vectors to induce cell alignment on the cusps.
6) The bioreactor is able to induce differentiation of stem cells into fibroblast-like cells.

Results show that the bioreactor is able to provide cell-friendly conditions and
create forces on the heart valve cusps, creating a controllable environment that will
be necessary in the conditioning of tissue engineered heart valves.
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CHAPTER 7: RECOMMENDATIONS
1) The next step that should be taken to improve this bioreactor is to increase the sample
size so multiple valves can be tested concurrently. This will be important when
statistically significant data is necessary. A multiple valve bioreactor should be
designed in the near future.
2) Improving the flow rates and pressures is also important to be able to reach and
exceed the native physiological resting conditions. A different type of pumping
mechanism such as a CAM driven device might be necessary instead of a pneumatic
pump.
3) An improved method of assembling the bioreactor and changing the culture media
should be investigated. This would create less opportunity for intial contamination
and allow the experiments to run longer with less risk of contamination.
4) A long term experiment should be performed with stem cells to examine the selfrepairing capabilities of tissue engineered heart valves.

The bioreactor approach should be continually developed to study multiple aspects
of tissue engineered heart valve development and heart valve pathology.
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Appendix A:

Design Documentation

Client Questionnaire
1) How is the bioreactor to be used?
- to test function?
- to condition?
- to measure mechanical properties?
- to transport a finished product to the hospital for implantation?
- to provide information regarding formation process of 3D tissues
- to provide information regarding development of the cells
- to establish a uniform distribution of cells on a 3D scaffold/facilitate cell seeding
- other?
2) What mechanical forces will be important to measure?
- shear stress
- fluid speed
- fluid density
- pressure drop across tissue
- total pressure magnitudes
- pressure waveform
- negative pressure anywhere
- flow waveform
- flow rate
- stroke volume
- frequency
- other
3) What mechanical forces will be important to regulate?
- shear stress
- fluid speed
- fluid density
- pressure drop across tissue
- total pressure magnitudes
- pressure waveform
- negative pressure anywhere
- flow waveform
- flow rate
- stroke volume
- frequency
- other
4) How many samples would you like to run at once?
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5) What is your estimate of what the cost should be?
6) What is the maximum amount of money you would like to spend, if known?
7) What types of sterilization are available on campus?
8) What nutrients will be important to measure?
- O 2 (pO 2 )
- CO 2 (pCO 2 )
- glucose
- temperature
- pH
- other
9) What nutrients will be important to regulate?
- O 2 (pO 2 )
- CO 2 (pCO 2 )
- glucose
- temperature
- pH
- other
10) How many days should the system be able to run?
11) What methods of attachment of the tissue to the bioreactor are possible or preferred?
12) How well do gasses and nutrients / wastes diffuse through the pericardium and other
material used? How thick is the material to be used?
13) What will the shape of the “heart valve” be? OR: What are the sizes of the vascular
grafts?
- leaflets only
- leaflets with some aorta
- leaflets on a ring
- leaflets with aorta and something on other side
- other
14) What diameter tissues will be used
15) How much user interaction/manipulation is acceptable?
- all computer controlled
- adjust valves with a screwdriver
- automatic measurements vs. computer-controlled readings
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16) What type of cells or other materials will be used and what are their mechanical and
chemical / nutritional requirements?
17) What are the values you would like to have available for mechanical forces?
- embryonic conditions
- newborn conditions
- slow then increase in pressure and flow rate
- values in numbers…
- other
18) What are the values you would like to have available for nutrient levels?
- embryonic conditions
- newborn conditions
- increasing with time
- values in numbers…
- other
19) Should the forces in the radial, circumferential, and longitudinal directions vary? If so,
how?

20) Are there any other comments, wishes, or suggestions you wish to see implemented
in the design of this first phase of the bioreactor? This is a chance for you to tell me
what YOU want out of the bioreactor if I have missed anything in the previous
questions. Please, give me input.
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Attributes List
Provide physiological pressure
Provide physiological flow of nutrient medium
Be contamination-resistant
Be maximally sterile
Have adjustable pulsatile flow (50-2000 mL/min)
Have varying levels of pressure (10-240 mmHg)
Be compact
Fit inside an incubator
Provide optimal gas supply
Provide stable temperature
Provide “instantaneous” flow of fluid through material to be tested – flow waveform
Have adjustable stroke volume of ventilator
Have adjustable ventilation rate of ventilator
Expose developing tissue to “correct” physiological “signals”
Allow long term testing
Be (largely) self reliant (Utilized with additional sophisticated equipment)
Be very robust
Be easy to clean and sterilize (ethylene oxide?)
Be transparent
Allow easy attachment of valve to system
Test up to ~10 samples at one time
Provide flow conditions similar to those of natural heart valves
Establish a uniform distribution of cells on a 3D scaffold
Maintain desired concentration of gases and nutrients in culture medium
Provide efficient mass transfer to the growing tissue
Expose developing tissue to physical stimuli
Provide information regarding formation process of 3D tissues, which originate from the
isolated cells
Control biomechanical environment
Control biochemical environment
Control pH
Control O 2 (pO 2 )
Control CO 2 (pCO 2 )
Control glucose
Be basic / not complicated / simple
Fluid flow: composition, flow rate, pressure, temperature (heat supply)
Mechanical force: pulsatile forces, pressure, flow rate, shear stress, frequency, stroke rate,
stroke volume
Be adaptable to multiple cardiovascular applications
Be user friendly
Be time efficient
Have quick setup
Be repeatable
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Objectives, Functions, and Constraints Lists
Objectives:
Should be compact / small
Must be very robust / durable
Should be made of durable materials
Machinery should be of good quality
Must be repairable
Must be able to separate into individual parts
Parts must be replaceable
Should be adaptable to multiple cardiovascular applications
Tissue-mount should be changeable for different tissues
Tissue-mount should be adjustable for different sizes and variations of tissue
Applied forces should be adjustable
Nutrient / waste levels should be adjustable
Should be user friendly
Should be basic / simple
Should have few parts requiring multiple adjustments
Should have few components
Should be time efficient
Should have quick setup
Should have easy setup
Should facilitate easy attachment of cardiovascular construct to the system
Should be (largely) self reliant (little manual work by user required to change
settings – screwdriver adjustments OK)
Must be repeatable
Must be sterile
Must be sterilizible (ethylene oxide?)
Must be contamination-resistant
Should be transparent
Should be easy to clean
Should be affordable to produce ($2500-$5000)
Constraints:
Must fit inside an incubator (how of controlling temp and pH) – means of the function
Must cost less than ~$5000
Material must not degrade in the presence of liquids
Requirements:
Vascular size changes monitored by video image capture
Minimize medium volume
Change medium in a sterile manner
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Functions:
Provide information regarding formation process of 3D tissues (visually see 3D structure)
Facilitate cell seeding and establish a uniform distribution of cells on a 3D scaffold (cells
may be placed on scaffold after scaffold is attached to incubator)
Test function the cardiovascular tissue (open and close heart valve or pump fluid through
vascular graft)
Hold 3-6 samples at once
Condition cardiovascular tissues for both 2-3 weeks and 5-6 months (why of
maintaining sterility)
Hold the cardiovascular tissue being tested
Display all settings and levels in a compact and understandable manner
Provide proper nutrient and waste transport to and from the tissue (pediatric conditions
for valves, adult for grafts)
Maintain temperature at 37°C (incubator)
Maintain pH at 7.2-7.4 (incubator / CO 2 )
Control CO 2 (pCO 2 ) (incubator)
Maintain high levels of O 2 (pO 2 ) (~20%?)
Control glucose levels
Apply proper forces to a cardiovascular tissue (pediatric conditions for valves, adult for
grafts)
Control pressure waveform over cardiac cycle
Control pressure drop across tissue (160/100 mmHg for heart valve)
Control flow waveform over cardiac cycle
Control flow rate (50-2000 mL/min?)
Control stroke volume
Control frequency (60-70 bpm)
Control shear stress
Control fluid speed
Control fluid density
Controlling fluid composition
Measure forces to cardiovascular tissue
Pressure drop across tissue
Pressure waveform over cardiac cycle
Flow rate
Stroke volume
Frequency
Shear stress
Fluid speed
Fluid density
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Pair-wise Comparison Charts
Dan, Aggie, Betsy, and Tom,

On the following charts, please compare the items in the left column to each item in the
top row, deciding which one is a more important quality for the bioreactor to have. These
are very broad and basic goals/objectives that the bioreactor is to achieve. Some are more
important than others and this will help me focus on what you believe to be the most
important areas.

I included a “tree” to help you visualize which goals are sub-goals, etc.

Scoring:
Item in left column is more important than item in top row: 1
Item in left column is equally important as item in top row: 0.5
Item in left column is less important than item in top row: 0
Do not fill in the gray boxes (they are duplicates of the white boxes)

This is only to get your views on RELATIVE importance

Thank you,
Lee
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Main Objectives
Adaptable to
User
Affordable
Compact
Multiple
Objectives PCC
Durable
Repeatable Sterile
Total
to Produce
or Small
Cardiovascular Friendly
Applications
Compact or
Small

XXXX

0

2

1

1

1

1

6

Durable

3

XXXX

3

2

1

2

4

15

Adaptable to
Multiple
Cardiovascular
Applications

2

0

XXXX

1

0

0

1

4

User Friendly

3

1

3

XXXX

0

2

2

11

Repeatable

3

3

4

4

XXXX

3

4

21

Sterile

3

1

3

2

1

XXXX

3

13

Affordable to
Produce

3

0

3

2

0

1

XXXX

9

Repeatable
Durable
Sterile
User Friendly
Affordable
Compact
Adaptable
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Sub-objective: Durable
Durable

Made of Durable
Materials

High Quality
Machinery

Made of Durable
Materials

XXXX

1

1

2

High Quality Machinery

0

XXXX

1

1

Repairable

2

2

XXXX

4

Repairable Total

Repairable
Durable materials
High quality machinery
Sub-sub-objective: Repairable
Repairable

Able to be
Replaceable
Total
separated into
parts
multiple parts

Able to be separated
into multiple parts

XXXX

0

0

Replaceable parts

1

XXXX

1

Replaceable parts
Able to be separated
Sub-objective: Adaptable to multiple cardiovascular applications
Adaptable to multiple
cardiovascular
applications
Changeable tissue-mount
for different tissues
Changeable tissue-mount
for different sizes and
variations of tissue

Changeable
Changeable tissue-mount
Adjustable
Adjustable
tissue-mount for
for different sizes and
nutrient and Total
applied forces
different tissues
variations of tissue
waste levels
XXXX

0

1

1

2

3

XXXX

1

2

6

Adjustable applied forces

3

3

XXXX

3

9

Adjustable nutrient and
waste levels

3

0

0

XXXX

3

Adjustable applied forces
Changeable tissue shapes and sizes
Adjustable nutrient and waste levels
Changeable tissues
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Sub-objective: User friendly
Facilitate easy
(Largely)
Total
attachment of
self-reliant
cardiovascular tissue

User Friendly

Basic / simple

Time
efficient

Basic / simple

XXXX

1

0

2

3

Time efficient

2

XXXX

0

2

4

Facilitate easy
attachment of
cardiovascular tissue

3

2

XXXX

2

7

(Largely) self-reliant

2

2

2

XXXX

6

Easy attachment of tissue
Self reliant
Time efficient
Basic, simple
Sub-sub-objective: Basic / simple
Have few parts
Basic / not
Have few
Total
requiring multiple
components
complicated / simple
adjustments
Have few parts
requiring multiple
adjustments

XXXX

1

1

Have few components

1

XXXX

1

Multiple adjustments – Few components
Sub-sub-objective: Time efficient
Time efficient Quick setup Easy setup Total
Quick setup

XXXX

1

1

Easy setup

2

XXXX

2

Easy setup
Quick setup
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Sub-objective: Sterile
ContaminationEasy to
Transparent
Total
resistant
clean

Sterile

Sterilizible

Sterilizible

XXXX

1

1

1

3

Contaminationresistant

1

XXXX

0

1

2

Transparent

1

1

XXXX

1

3

Easy to clean

1

0

0

XXXX

1

Sterilizible – Transparent
Contamination resistant
Easy to clean
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Main objectives:
1) Repeatable
2) Durable
3) Sterile
4) User friendly
5) Affordable
6) Compact
7) Adaptable
Sub-objective: Durable
1) Repairable
2) Durable materials
3) High quality machinery
Sub-sub-objective: Repairable
1) Replaceable parts
2) Able to be separated
Sub-objective: Adaptable
1) Adjustable applied forces
2) Changeable tissue shapes and sizes
3) Adjustable nutrient and waste levels
4) Changeable tissues
Sub-objective: User friendly
1) Easy attachment of tissue
2) Self reliant
3) Time efficient
4) Basic, simple
Sub-sub-objective: Basic / simple
1) Multiple adjustments – Few components
Sub-sub-objective: Time efficient
1) Easy setup
2) Quick setup
Sub-objective: Sterile
1) Sterilizible – Transparent
2) Contamination resistant
3) Easy to clean
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Appendix B:

Digitally Inverted DAPI Images
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